Novartis announced Phase II primary endpoint data showing the investigational, first-in-class, oral, targeted factor B inhibitor iptacopan reduced protein in the urine – an increasingly recognized surrogate marker correlating with progression to kidney failure – and showed promise in stabilizing kidney function in patients with IgA nephropathy (IgAN).
Men with a deadly form of advanced prostate cancer who failed other treatments survived four months longer after getting an experimental tumor-targeting radiation therapy from Swiss drugmaker Novartis, data released on June 3 showed.
The U.S. Food and Drug Administration approved Novartis’ blockbuster drug Cosentyx (secukinumab) for pediatric patients aged 6 years and older with moderate-to-severe plaque psoriasis. The new approval for Cosentyx marks the first for a pediatric patient population in the United States.
Novartis cut three Phase III trials of the eye therapy Beovu (brolucizumab) after the studies showed higher rates of intraocular inflammation with frequent dosing intervals of the therapy.
The U.S. Supreme Court on May 17 dashed Novartis AG’s hopes of launching a generic version of Amgen Inc.’s multibillion-dollar rheumatoid arthritis medicine Enbrel, declining to hear the company’s challenge to two patents on the drug.
Novartis said on Tuesday that a large British study of the Swiss drugmaker’s cholesterol-lowering medicine Leqvio is not expected to be completed until 2026, a year later than expected, as Covid-19 infections made participant recruitment difficult.
The tenth annual Pharmaceutical Innovation Index, released April 21, sees Eli Lilly top the industry for the first time. The Pharmaceutical Invention Index, a ranking of the industry’s best pipelines, rated Bristol Myers Squibb as No. 1.
None of the 43 antibiotics in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization cautioned on April 15.
The U.S. Food and Drug Administration approved a prefilled syringe for self-injection of the allergic diseases treatment Xolair developed by Novartis and Genentech, a Roche company.
Artios Pharma entered into a global research collaboration with Novartis for the purpose of discovering and validating next-generation DNA damage response (DDR) targets and enhancing Novartis’ radioligand therapies.
